Literature DB >> 16356651

A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder.

Jayashri Kulkarni1, Kathryn A Garland, Antonietta Scaffidi, Barbara Headey, Robyn Anderson, Anthony de Castella, Paul Fitzgerald, Susan R Davis.   

Abstract

We tested and compared the use of two adjunctive hormonal agents, tamoxifen and medroxyprogesterone acetate (MPA), for the treatment of acute mania or hypomania. A total of 13 women with acute Bipolar Affective Disorder in the manic or hypomanic phase were recruited from a clinical population to participate in this 28-day, three-arm, double blind, placebo-controlled study. The women who received tamoxifen exhibited significant improvement in symptoms of mania from baseline to final assessment compared with the placebo group. The MPA group improved more than the placebo group. Further exploration of tamoxifen as a useful adjunct in the treatment of acute manic symptoms in women with Bipolar Affective Disorder is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356651     DOI: 10.1016/j.psyneuen.2005.11.001

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  34 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 2.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

3.  Protein kinase C inhibition: a target for treatment of mania.

Authors:  Mina Hah; Joachim F Hallmayer
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

Review 4.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 5.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 6.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 7.  A role for the PKC signaling system in the pathophysiology and treatment of mood disorders: involvement of a functional imbalance?

Authors:  Erika Abrial; Guillaume Lucas; Hélène Scarna; Nasser Haddjeri; Laura Lambás-Señas
Journal:  Mol Neurobiol       Date:  2011-10-05       Impact factor: 5.590

Review 8.  A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.

Authors:  Nancy DiazGranados; Carlos A Zarate
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

Review 9.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-11       Impact factor: 3.790

10.  Human disease-drug network based on genomic expression profiles.

Authors:  Guanghui Hu; Pankaj Agarwal
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.